SGLT2i Use Linked to Reduced Risk for Flare in Adults With Gout, T2D
MONDAY, July 24, 2023 -- For patients with gout and type 2 diabetes, sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk for recurrent gout flares and gout-primary emergency department visits and hospitalizations,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Diabetes | Diabetes Type 2 | Emergency Medicine | Endocrinology | Gout | Pharmaceuticals | Sodium